Literature DB >> 7749839

Apolipoprotein A-II production rate is a major factor regulating the distribution of apolipoprotein A-I among HDL subclasses LpA-I and LpA-I:A-II in normolipidemic humans.

K Ikewaki1, L A Zech, M Kindt, H B Brewer, D J Rader.   

Abstract

HDLs are heterogeneous in their apolipoprotein composition. Apolipoprotein (apo) A-I and apoA-II are the major proteins found in HDL and form the two major HDL subclasses: those that contain only apoA-I (LpA-I) and those that contain both apoA-I and apoA-II (LpA-I:A-II). Substantial evidence indicates that these two subclasses differ in their in vivo metabolism and effect on atherosclerosis, with LpA-I the more specifically protective subfraction against atherosclerosis. The purpose of this study was to investigate the effect of apoA-I and apoA-II production and catabolism on plasma LpA-I and LpA-I:A-II levels. Fifty normolipidemic subjects (those with HDL cholesterol levels in the top and bottom tenth percentiles were excluded) underwent kinetic studies with radiolabeled apoA-I and apoA-II, and the kinetic parameters of apoA-I and apoA-II were correlated with LpA-I and LpA-I:A-II levels. ApoA-I levels were strongly correlated with apoA-I residence times and less strongly correlated with apoA-I production rates. In contrast, apoA-II levels were correlated only with apoA-II production rates and not with apoA-II residence times. Levels of apoA-I in LpA-I were correlated with apoA-I residence times, whereas levels of apoA-I in LpA-I:A-II were correlated primarily with apoA-II production rates. The fraction of apoA-I in LpA-I was highly inversely correlated with apoA-II production rate (r = -.67, P < .001). In multiple regression analysis, apoA-II production rate was the most significant independent variable determining percent apoA-I in LpA-I among all the kinetic parameters.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7749839     DOI: 10.1161/01.atv.15.3.306

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  11 in total

Review 1.  Molecular regulation of HDL metabolism and function: implications for novel therapies.

Authors:  Daniel J Rader
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

2.  Apolipoproteins A-I, A-II and E are independently distributed among intracellular and newly secreted HDL of human hepatoma cells.

Authors:  Baiba K Gillard; Hu-Yu Alice Lin; John B Massey; Henry J Pownall
Journal:  Biochim Biophys Acta       Date:  2009-07-25

3.  Setting the course for apoAII: a port in sight?

Authors:  Henry J Pownall; Baiba K Gillard; Antonio M Gotto
Journal:  Clin Lipidol       Date:  2013-10

4.  Formation of apolipoprotein-specific high-density lipoprotein particles from lipid-free apolipoproteins A-I and A-II.

Authors:  M A Clay; D A Cehic; D H Pyle; K A Rye; P J Barter
Journal:  Biochem J       Date:  1999-02-01       Impact factor: 3.857

Review 5.  Speciated High-Density Lipoprotein Biogenesis and Functionality.

Authors:  C Rosales; W S Davidson; B K Gillard; A M Gotto; H J Pownall
Journal:  Curr Atheroscler Rep       Date:  2016-05       Impact factor: 5.113

6.  Preparation and activity analysis of recombinant human high-density lipoprotein.

Authors:  Manman Su; Weiqin Chang; Kaiyao Shi; Dingding Wang; Mingxing Wang; Tianmin Xu; Weiqun Yan
Journal:  Assay Drug Dev Technol       Date:  2012-08-16       Impact factor: 1.738

7.  Two regulatory elements of similar structure and placed in tandem account for the repressive activity of the first intron of the human apolipoprotein A-II gene.

Authors:  J P Bossu; F L Chartier; J C Fruchart; J Auwerx; B Staels; B Laine
Journal:  Biochem J       Date:  1996-09-01       Impact factor: 3.857

8.  Hyperalphalipoproteinemia in human lecithin cholesterol acyltransferase transgenic rabbits. In vivo apolipoprotein A-I catabolism is delayed in a gene dose-dependent manner.

Authors:  M E Brousseau; S Santamarina-Fojo; L A Zech; A M Bérard; B L Vaisman; S M Meyn; D Powell; H B Brewer; J M Hoeg
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

9.  Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.

Authors:  A Hiukka; E Leinonen; M Jauhiainen; J Sundvall; C Ehnholm; A C Keech; M R Taskinen
Journal:  Diabetologia       Date:  2007-07-26       Impact factor: 10.122

10.  Phospholipids mediated conversion of HDLs generates specific apoA-II pre-beta mobility particles.

Authors:  Malgorzata Wróblewska; Barbara Kortas-Stempak; Andrzej Szutowicz; Tadeusz Badzio
Journal:  J Lipid Res       Date:  2008-12-09       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.